Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OB756 in ruxolitinib-intolerant intermediate-2/high-risk myelofibrosis
CTR20212361Phase 2Active
- Sponsor
- Huadong Medicine
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bewintinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), sponsored by Huadong Medicine. Started Mar 2022; status: active.
02
Drugs
bewintinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)
Beyond the preview
Go deeper on CTR20212361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212361.